How Does Semaglutide Work? Mechanism, Half Life, and What the Trials Showed

Semaglutide is a long acting analogue of glucagon like peptide 1, a hormone the gut releases after a meal. It binds the same receptor the natural hormone binds, but it stays bound for days instead of minutes. That change in duration is the whole trick: a brief signal that a meal has arrived becomes a continuous one. The downstream effects are slower stomach emptying, glucose dependent insulin release, suppressed glucagon, and a quieter appetite. Weight loss follows from eating less, not from burning more.

This page works through the mechanism piece by piece, the pharmacokinetics that make it a weekly injection, what the STEP trials actually measured, and why weight returns when the drug stops. For the escalation schedule see the semaglutide dosage guide, and for tolerability see semaglutide side effects. This is research use information and none of it is medical advice.

What Semaglutide Is Built From

Native GLP-1 has a half life of roughly two minutes. The enzyme dipeptidyl peptidase 4 clips it almost as fast as the intestine releases it, which suits a hormone whose job is to report that food has arrived and then get out of the way. It is useless as a drug.

Semaglutide is that peptide with three structural changes that fix the problem. The amino acid at position 8 is swapped for alpha aminoisobutyric acid, which DPP-4 cannot cut. A long fatty diacid chain is attached through a spacer near position 26, and that chain binds reversibly to albumin in the blood. Albumin bound drug is shielded from renal clearance and released back into circulation slowly. What remains is about 94 percent sequence identity with human GLP-1 and a half life measured in days.

Everything that follows is ordinary GLP-1 biology held on far longer than the body would ever hold it on by itself. That framing explains both the benefits and most of the complaints.

The Pancreatic Side: Insulin and Glucagon

On the beta cell, GLP-1 receptor activation raises cyclic AMP and amplifies insulin secretion. The qualifier that matters is that the amplification is glucose dependent. When blood glucose is low the signal does very little, which is why semaglutide used alone carries a low hypoglycaemia risk compared with insulin or a sulfonylurea. Paired with either of those, the risk comes from the partner drug rather than from semaglutide.

On the alpha cell it pushes the other way, suppressing glucagon release after a meal. Excess postprandial glucagon is a large part of why blood glucose overshoots in type 2 diabetes, so for some people that effect does more work than the insulin one.

Neither of these is the weight loss mechanism. They are the reason the molecule was developed as a diabetes drug first, with weight loss showing up as a consistent secondary finding that was later chased on purpose.

Gastric Emptying

GLP-1 receptor activation slows the rate at which the stomach passes food into the small intestine, through vagal signalling and through direct effects on gastric motility. Food sits longer, the stomach stays distended longer, and stretch receptors keep reporting fullness well after the meal ends.

Two things follow. A smaller meal now produces the fullness a larger one used to, which is the part people notice and like. And most of the gastrointestinal complaints live here: nausea, reflux, early satiety and constipation are the same slowing experienced as a problem rather than a benefit. They are not a separate toxicity, they are the mechanism at a dose the person has not adapted to yet.

The delay is also partly adaptive. It is strongest early in treatment and immediately after a dose step, then attenuates with continued exposure, which is why the nausea of week two is usually not the nausea of month six.

The Appetite Centres

The part responsible for sustained weight loss is central. GLP-1 receptors are expressed in the hypothalamus, particularly in the arcuate nucleus, and in the brainstem at the area postrema and the nucleus of the solitary tract. Semaglutide is a large, albumin bound molecule and does not cross the blood brain barrier freely, so it reaches these regions mainly where the barrier is leaky, at the circumventricular organs, and indirectly through vagal afferents carrying signals up from the gut.

In the arcuate nucleus, receptor activation favours the POMC and CART expressing neurons that signal satiety and dampens the AgRP and NPY neurons that drive hunger. What people report is rarely nausea driven avoidance of food. It is closer to the disappearance of a background hum, the constant low level interest in eating that is often described as food noise. Reward related circuitry responds too, which is why preference frequently shifts away from high fat and high sugar foods rather than every portion simply shrinking in proportion.

The uncomfortable part of the architecture is that the brainstem region doing appetite suppression is also where nausea and vomiting are generated. The two effects share hardware, which is why they tend to arrive together and why titration exists.

Pharmacokinetics: Why It Is a Weekly Injection

Because exposure is close to identical across the approved subcutaneous sites, site choice is a comfort and rotation decision rather than a potency one. The practical detail is in where to inject semaglutide, and if you are converting a milligram dose into marks on a barrel, the semaglutide dosage calculator does the arithmetic.

Why the Dose Is Escalated Slowly

The weight management schedule steps up roughly every four weeks, starting well below any dose expected to do much. That schedule exists for tolerability, not because the low steps are treatment doses. Two facts sit behind it. Gastrointestinal effects are dose related and adapt with exposure, so time at a dose buys tolerance. And steady state takes four to five weeks, so a four week step is the minimum interval at which the previous dose has been fully expressed before the next is added.

The common mistake is reading slow progress at a low step as failure of the drug, when at the starting dose there is simply not much drug at steady state yet. Holding a step longer than four weeks is a normal adjustment rather than a failure, and the dosage guide covers how those holds are usually handled.

What the STEP Trials Showed

STEP 1 is the trial most figures trace back to. It randomised adults with obesity, or overweight with a weight related condition and without diabetes, to semaglutide 2.4 mg weekly or placebo, both alongside lifestyle intervention, for 68 weeks. Mean body weight change was 14.9 percent with semaglutide against 2.4 percent with placebo, and roughly a third of participants on drug lost at least 20 percent of their starting weight.

Two things are worth pulling out of that table. The result is consistently smaller in people with type 2 diabetes, which is a reproducible pattern across this drug class rather than a quirk of one study. And STEP 4 is the cleanest demonstration that the effect is maintained only while the drug is present: the same people, on the same protocol, moved in opposite directions the moment the injection stopped.

Why Weight Returns After Stopping

In the STEP 1 extension, participants who came off semaglutide had regained roughly two thirds of the weight they had lost within a year, and most of the improvement in cardiometabolic markers moved back with it. That is not a failure of adherence and it is not evidence the drug broke something. It is what the mechanism predicts.

Semaglutide does not retrain appetite, it substitutes for a signal. Remove the molecule and the gastric emptying rate normalises, the arcuate nucleus stops receiving the extra satiety input, and hunger returns to something like its pre treatment level, now acting on a body that is smaller and therefore burns fewer calories at rest. The honest framing is that semaglutide behaves like a treatment for a chronic condition rather than a course of something. Broader context on how this compound sits against the others in the category is in weight loss peptides, and the head to head with the dual agonist is in semaglutide versus tirzepatide.

Compounded and Research Grade Semaglutide

Everything above describes the molecule studied in the STEP programme, delivered in a characterised pharmaceutical product at a known concentration. Compounded semaglutide is a different supply route, usually a vial of lyophilised powder that has to be reconstituted and drawn by the person using it, and sometimes a salt form such as semaglutide sodium or semaglutide acetate rather than the base studied in the trials. Salt forms are not automatically inert, but they are also not the entity the efficacy data was generated with.

Research grade vials sold for laboratory use are a third category again, with no pharmacy oversight, no dispensing check and content that depends entirely on the supplier's own testing. That is the category this site covers, under research use only framing, and the distinctions are set out in compounded semaglutide. The mechanism does not change with the supply route. What changes is how confident anyone can be about the number on the label.

Key Takeaways

• Semaglutide is a GLP-1 analogue engineered for DPP-4 resistance and albumin binding, giving a half life of about a week
• It amplifies insulin release only when glucose is high, and suppresses glucagon after meals
• Slowed gastric emptying explains both the early fullness and most of the nausea
• Sustained appetite suppression is central, acting on hypothalamic and brainstem circuits
• STEP 1 showed 14.9 percent mean weight loss at 68 weeks on 2.4 mg weekly against 2.4 percent on placebo
• Weight returns after stopping because the drug substitutes for a signal rather than resetting it
• Compounded and research grade material shares the mechanism but not the manufacturing assurance

Frequently Asked Questions

How does semaglutide work for weight loss?

It acts as a long lasting GLP-1 receptor agonist. Two effects drive weight loss. It slows gastric emptying, so a smaller meal produces the fullness a larger one used to, and it activates appetite regulating circuits in the hypothalamus and brainstem, reducing the background drive to eat. Both reduce energy intake. Semaglutide does not raise energy expenditure, so the weight loss comes from eating less rather than from burning more.

How long does semaglutide take to work?

Appetite effects are often noticeable within the first week or two, but the starting dose is a tolerability step rather than a treatment dose, and the drug takes four to five weeks to reach steady state at any given dose. Meaningful weight change is therefore usually assessed over months, not weeks. In STEP 1 the weight curve was still descending at around week 60 of a 68 week trial.

What is the half life of semaglutide?

About one week, which is why it is injected once weekly on a fixed day. The long half life comes from two engineering changes: an amino acid substitution at position 8 that blocks the DPP-4 enzyme, and a fatty diacid chain that binds albumin and creates a slow release reservoir in the blood. After the final dose it takes roughly five weeks to clear.

Does semaglutide speed up metabolism?

No. There is no evidence that semaglutide raises resting energy expenditure, and the plausible direction is the opposite, since a smaller body burns fewer calories at rest. The entire effect runs through reduced energy intake. This matters when planning what happens after treatment, because appetite returns while the lower resting expenditure of a smaller body does not automatically reverse.

Why do people regain weight after stopping semaglutide?

Because the drug substitutes for an appetite signal rather than resetting one. When it clears, gastric emptying normalises and the hypothalamic satiety input disappears, so hunger returns to roughly its pre treatment level. In the STEP 1 extension, participants regained about two thirds of the weight they had lost within a year of stopping, and STEP 4 showed the same split prospectively.